A.R.T. Advisors’s Moleculin Biotech MBRX Stock Holding History

A.R.T. Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-1	Closed	-$31K	–	1561
2019 Q3	$31K	Buy	+1	New	+$51.7K	﹤0.01%	1351

Other funds holding MBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $84.4B AUM 20.16% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Whitegate Investment Counselors Concord, New Hampshire $343M AUM 8.81% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

A.R.T. Advisors's MBRX Position: Q4 2019 in Review

A.R.T. Advisors sold out of Moleculin Biotech (MBRX) in Q4 2019, closing a stake of 1 share — an estimated $31K sold.

A.R.T. Advisors first reported a position in MBRX in Q3 2019 and held it in 1 quarter. The position peaked at $31K in Q3 2019. 11 funds tracked by Wall St. Rank hold MBRX as of Q4 2019.

A.R.T. Advisors reported no remaining Moleculin Biotech position as of Q4 2019 after selling out during the quarter.
A.R.T. Advisors sold 1 Moleculin Biotech share in Q4 2019, an estimated $31K.
A.R.T. Advisors first reported a position in Moleculin Biotech in Q3 2019 and held it in 1 quarter.
A.R.T. Advisors's Moleculin Biotech position peaked at $31K in Q3 2019.
11 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2019.

Based on A.R.T. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.